- In May 2024, Bayer AG announced updated clinical trial results for Xofigo (radium Ra 223 dichloride), which demonstrated a 14% improvement in overall survival among patients with symptomatic bone-predominant mCRPC. This development underscores Bayer’s ongoing commitment to expanding therapeutic benefits for patients through radiopharmaceutical innovations. The data positions Xofigo as a key component of combination treatment regimens and is expected to significantly boost Bayer’s share in the radiotherapy segment, which accounted for 11.8% of the global market revenue in 2024
- In April 2024, Pfizer Inc. received FDA approval for the expanded indication of Talzenna (talazoparib) in combination with enzalutamide for patients with mCRPC harboring homologous recombination repair (HRR) gene mutations. This approval marks a pivotal advancement in precision oncology, offering targeted treatment options to a broader patient population. The HRR-targeted therapy segment is projected to grow at a CAGR of 19.6% from 2025 to 2032
- In March 2024, Janssen Pharmaceutical Companies of Johnson & Johnson launched A Study of Niraparib and Abiraterone Acetate (MAGNITUDE Trial) in Europe, aiming to evaluate the efficacy of the combination therapy in newly diagnosed mCRPC patients with and without HRR mutations. This strategic move is expected to enhance Janssen’s market penetration in Europe, where the company held a 16.2% market share in 2024, by addressing both biomarker-positive and biomarker-negative populations
- In February 2024, Astellas Pharma Inc. and Pfizer announced new long-term efficacy data for Xtandi (enzalutamide) from the PROSPER and PREVAIL trials. The combined findings revealed a 21% improvement in radiographic progression-free survival (rPFS) over standard of care. Xtandi continues to dominate the androgen receptor signaling inhibitor segment, which represented 34.5% of the global treatment market share in 2024, and is forecasted to retain leadership through 2032
- In January 2024, Sanofi initiated a Phase 1/2 clinical trial evaluating a first-in-class bispecific T-cell engager (BiTE) immunotherapy for metastatic prostate cancer. This move signals Sanofi’s entry into the immunotherapy domain for mCRPC, a segment currently in its early stages but projected to grow at an exponential CAGR of 25.3% due to increasing demand for durable, targeted immunologic responses
- In December 2023, Myovant Sciences and Sumitomo Pharma reported promising real-world evidence supporting Orgovyx (relugolix), a once-daily oral GnRH receptor antagonist. The data showed faster testosterone suppression compared to injectable therapies, bolstering patient adherence and reducing cardiovascular risk profiles. The oral hormone therapy segment accounted for 29.4% of the total treatment market share in 2024, and the demand for convenient dosing formats is expected to drive its growth
